E. Kiwan

发表

Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma

B. Barlogie, E. Anaissie, F. van Rhee, 2008, Cancer.

Thalidomide and hematopoietic-cell transplantation for multiple myeloma.

John Crowley, Erik Rasmussen, Bart Barlogie, 2006, The New England journal of medicine.

Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model

B. Barlogie, E. Anaissie, S. Krishna, 2006, Bone Marrow Transplantation.

Clinical and biological features of multiple myeloma involving the gastrointestinal system.

B. Barlogie, G. Tricot, M. Zangari, 2006, Haematologica.

Neoadjuvant systemic treatment of breast cancer

I. Makhoul, E. Kiwan, 2011, Journal of surgical oncology.

Ninety Percent Sustained Complete Response (CR) Rate Projected 4 Years after Onset of CR in Gene Expression Profiling (GEP)-Defined Low-Risk Multiple Myeloma (MM) Treated with Total Therapy 3 (TT3): Basis for GEP-Risk-Adapted TT4 and TT5

B. Barlogie, J. Shaughnessy, E. Anaissie, 2008 .

Cytopenia, dysplasia, and monocytosis: a precursor to chronic myelomonocytic leukemia or a distinct subgroup? Case reports and review of literature.

Z. Singh, G. Post, A. Maddox, 2011, Clinical lymphoma, myeloma & leukemia.

The Clinical Spectrum of Stenotrophomonas (Xanthomonas) Maltophilia Respiratory Infection

E. Anaissie, S. Vartivarian, Konstantinos Papadakis, 2000, Seminars in respiratory and critical care medicine.

Metronomic chemoimmunotherapy in a patient with refractory Waldenström's macroglobulinemia

B. Barlogie, E. Anaissie, G. Tricot, 2005, Leukemia & lymphoma.

Hyperammonemia and encephalopathy in patients with multiple myeloma

B. Barlogie, G. Tricot, M. Zangari, 2007, American journal of hematology.